(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 November 2023 (16.11.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/217851 A1

(51) International Patent Classification:
C07D 403/14 (2006.01) *A61P 29/00* (2006.01)
C07D 413/14 (2006.01) *A61P 35/00* (2006.01)
C07D 417/14 (2006.01) *A61P 37/00* (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:
PCT/EP2023/062404

(22) International Filing Date:
10 May 2023 (10.05.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/364,549 11 May 2022 (11.05.2022) US

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **ROVIRA, Alexander R.**; 3210 Merryfield Row, San Diego, California 92121-1126 (US). **MURPHY, Stephen K.**; 3210 Merryfield Row, San Diego, California 92121-1126 (US). **LEBSACK, Alec D.**; 3210 Merryfield Row, San Diego, California 92121-1126 (US). **CHAI, Wenying**; 3210 Merryfield Row, San Diego, California 92121-1126 (US). **ENNY, Daniel**; 3210 Merryfield Row, San Diego, California 92121-1126 (US). **MAERTENS, Alexander**; 3210 Merryfield Row, San Diego, California 92121-1126 (US). **AMERIKS, Michael**; 3210 Merryfield Row, San Diego, California 92121-1126 (US).

(74) Agent: **WARNER, James Alexander** et al.; Carpmaels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2023/217851 A1

(54) Title: PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE



(I')

(57) Abstract: The present disclosure relates to compounds of Formula (I') that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventing or treating diseases such as inflammatory disorders and autoimmune disorders.